Development of potent monoclonal antibody auristatin conjugates for cancer therapy

Nature Biotechnology

Volumn 21, Issue 7, 2003, Pages 778-784

  Doronina, Svetlana O ^a   Toki, Brian E ^a   Torgov, Michael Y ^a   Mendelsohn, Brian A ^a   Cerveny, Charles G ^a   Chace, Dana F ^a   DeBlanc, Ron L ^a   Gearing, R Patrick ^a   Bovee, Tim D ^a   Siegall, Clay B ^a   Francisco, Joseph A ^a   Wahl, Alan F ^a   Meyer, Damon L ^a   Senter, Peter D ^a  

^a SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; CELLS; DRUG PRODUCTS; ESTERS; ONCOLOGY; SYNTHESIS (CHEMICAL);

DRUG POTENCY;

BIOTECHNOLOGY;

5 BENZOYLVALERIC ACID AURISTATIN E ESTER; AURISTATIN PE; CD30 ANTIGEN; DIPEPTIDE; DOLASTATIN 10 ANALOG; HYDRAZONE DERIVATIVE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AURISTATIN E CONJUGATE; MONOCLONAL ANTIBODY CAC10; MONOCLONAL ANTIBODY CBR96; MONOCLONAL ANTIBODY PHENYLALANYLLYSINE MONOMETHYLAURISTATIN E CONJUGATE; MONOCLONAL ANTIBODY VALYLCITRULLINE MONOMETHYLAURISTATIN E CONUGATE; MONOMETHYLAURISTATIN E; PROTEASE SENSITIVE DIPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG POTENCY; DRUG RELEASE; DRUG SAFETY; DRUG SPECIFICITY; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; LYSOSOME; METHODOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; THERAPEUTIC INDICES; THERAPY; TUMOR REGRESSION; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HUMANS; IMMUNOTOXINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; PROTEIN BINDING; TREATMENT OUTCOME;

ANIMALIA;

EID: 10744222473     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt832     Document Type: Article

References (31)

1. Carter, P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 1, 118-129 (2001).
2. Dillman, R.O. Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments. Cancer Invest. 19, 833-841 (2001).
3. King, K.M. & Younes, A. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma. Expert Rev. Anticancer Ther. 1, 177-186 (2001).
4. Schwartzberg, L.S. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit. Rev. Oncol. Hematol. 40, 17-24 (2001).
5. Yarden, Y. & Sliwkowski, M.X. Untangling the ErbB signaling network. Nat. Rev. Mol. Biol. 2, 127-137 (2001).
6. Dubowchik, G.M. & Walker, M.A. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol. Ther. 83, 67-123 (1999).
7. Bross, P.F. et al. Approval summary: gentuzamab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7, 1490-1496 (2001).
8. Hamann, P.R. et al. An anti-CD33 antibody calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug. Chem. 13, 40-46 (2002).
9. Hamann, P.R. et al. Gemtuzamab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. 13, 47-58 (2002).
10. Trail, P.A. et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261, 212-215 (1993).
11. Saleh, M.N. et al. Phase I trial of anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors. J. Clin. Oncol. 18, 2282-2292 (2000).
12. Liu, C. et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc. Natl. Acad. Sci. USA 93, 8618-8623 (1996).
13. Chari, R.V.J. et al. Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. Cancer Res. 55, 4079-4084 (1995).
14. Ojima, I. et al. Tumor-specific novel taxoid monoclonal antibody conjugates. J. Med. Chem. 45, 5620-5623 (2002).
15. Jain, R.K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 50, 814-819 (1990).
16. Dubowchik, G.M. et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug. Chem. 13, 855-869 (2002).
17. King, H.D. et al. Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains. J. Med. Chem. 45, 4336-4343 (2002).
18. Toki, B.E., Cerveny, C.G., Wahl, A.F. & Senter, P.D. Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs. J. Org. Chem. 67, 1866-1872 (2002).
19. de Groot, F.M., Damen, E.W. & Scheeren, H.W. Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor associated enzymes, and receptors. Curr. Med. Chem. 8, 1093-1122 (2001).
20. Trouet, A., Masquelier, M., Baurain, R. & Deprez-De Campeneere, D. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proc. Natl. Acad. Sci. USA 79, 626-629 (1982).
21. Pettit, G.R. The dolastatins. Fortschr. Chem. Org. Naturst. 70, 1-79 (1997).
22. Vaishampayan, U. et al. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma Clin. Cancer Res. 6, 4205-4208 (2000).
23. Madden, T. et al. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clin. Cancer Res. 6, 1293-1301 (2000).
24. Otani, M. et al. TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn. J. Cancer Res. 91, 837-844 (2000).
25. Pettit, G.R. & Barkoczy, J. Tumor inhibiting tetrapeptide bearing modified phenethyl amides. US 5, 635, 483 (1997).
26. Carl, P.L., Chakravarty, P.K. & Katzenellenbogen, J.A. A novel connector linkage applicable in prodrug design. J. Med. Chem. 24, 479-480 (1982).
27. Koblinski, J.E., Ahram, M. & Sloane, B.F. Unraveling the role of proteases in cancer. Clin. Chim. Acta 291, 113-135 (2000).
28. Wahl, A.F. et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 62, 3736-3742 (2002).
29. Satoh, T. & Hosokawa, M. The mammalian carboxylesterases: from molecules to functions. Annu. Rev. Pharmacol. Toxicol. 38, 257-288 (1998).
30. Schrappe, M. et al. Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27. Cancer Res. 52, 3838-3844 (1992).
31. Wallace, P.M. & Senter, P.D. In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate. Bioconjug. Chem. 2, 349-352 (1991).